口服塞马鲁肽在实际应用中的有效性和安全性；REVOLUTION 研究

IF 1 Q4 ENDOCRINOLOGY & METABOLISM Diabetes epidemiology and management Pub Date : 2024-03-04 DOI:10.1016/j.deman.2024.100209

Abdulrahman Alsheikh , Ali Alshehri , Saad Alzahrani , Anwar AlJammah , Fahad Alqahtani , Metib Alotaibi , Raed Aldahash , Amani M. Alhozali , Fahad Alsabaan , Mohammed Almehthel , Naser Aljuhani , Ali Aldabeis , Moneer Alamri , Waleed Maghawry , Naweed Alzaman , Alshaima Alshaikh , Omar M. Alnozha , Emad R Issak , Saud Alsifri

{"title":"口服塞马鲁肽在实际应用中的有效性和安全性；REVOLUTION 研究","authors":"Abdulrahman Alsheikh , Ali Alshehri , Saad Alzahrani , Anwar AlJammah , Fahad Alqahtani , Metib Alotaibi , Raed Aldahash , Amani M. Alhozali , Fahad Alsabaan , Mohammed Almehthel , Naser Aljuhani , Ali Aldabeis , Moneer Alamri , Waleed Maghawry , Naweed Alzaman , Alshaima Alshaikh , Omar M. Alnozha , Emad R Issak , Saud Alsifri","doi":"10.1016/j.deman.2024.100209","DOIUrl":null,"url":null,"abstract":"<div><h3>Aims</h3><p>This study seeks to provide insights into the practical application and effects of oral semaglutide in Saudi T2DM patients under routine medical supervision.</p></div><div><h3>Methods</h3><p>The primary outcome measure was the laboratory HbA1c. Secondary measures included fasting blood glucose (FBG), weight, and hypoglycemia. All variables were checked after six months and 12 months of initiation.</p></div><div><h3>Results</h3><p>The analysis of this study included 245 uncontrolled (HbA1c > 7 %) T2DM patients. The mean baseline HbA1c was 10.1 % (1.2). HbA1c was reduced by an average of 3.1 % (0.8) and 3.2 % (0.8) at 6 and 12 months, respectively. The frequency of hypoglycemia events in the last three months before semaglutide was initiated was 4.4 (1.1). The frequency of hypoglycemia events in the last three months was 2.2 (0.8) and 0.7 (0.4) at 6-month and 12-month follow-up visits, respectively. The percent reduction in body mass index (BMI) was an average of 13.0 % (1.4) and 19.7 % (3.4) at six months and 12 months, respectively. Lipid profile and blood pressure were improved at six months and 12 months.</p></div><div><h3>Conclusions</h3><p>Oral semaglutide provided substantial glycemic and weight-loss benefits in adult individuals with T2DM.</p></div>","PeriodicalId":72796,"journal":{"name":"Diabetes epidemiology and management","volume":"14 ","pages":"Article 100209"},"PeriodicalIF":1.0000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666970624000143/pdfft?md5=94b2da85bd56858ce5bfeb30f75ce245&pid=1-s2.0-S2666970624000143-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study\",\"authors\":\"Abdulrahman Alsheikh , Ali Alshehri , Saad Alzahrani , Anwar AlJammah , Fahad Alqahtani , Metib Alotaibi , Raed Aldahash , Amani M. Alhozali , Fahad Alsabaan , Mohammed Almehthel , Naser Aljuhani , Ali Aldabeis , Moneer Alamri , Waleed Maghawry , Naweed Alzaman , Alshaima Alshaikh , Omar M. Alnozha , Emad R Issak , Saud Alsifri\",\"doi\":\"10.1016/j.deman.2024.100209\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Aims</h3><p>This study seeks to provide insights into the practical application and effects of oral semaglutide in Saudi T2DM patients under routine medical supervision.</p></div><div><h3>Methods</h3><p>The primary outcome measure was the laboratory HbA1c. Secondary measures included fasting blood glucose (FBG), weight, and hypoglycemia. All variables were checked after six months and 12 months of initiation.</p></div><div><h3>Results</h3><p>The analysis of this study included 245 uncontrolled (HbA1c > 7 %) T2DM patients. The mean baseline HbA1c was 10.1 % (1.2). HbA1c was reduced by an average of 3.1 % (0.8) and 3.2 % (0.8) at 6 and 12 months, respectively. The frequency of hypoglycemia events in the last three months before semaglutide was initiated was 4.4 (1.1). The frequency of hypoglycemia events in the last three months was 2.2 (0.8) and 0.7 (0.4) at 6-month and 12-month follow-up visits, respectively. The percent reduction in body mass index (BMI) was an average of 13.0 % (1.4) and 19.7 % (3.4) at six months and 12 months, respectively. Lipid profile and blood pressure were improved at six months and 12 months.</p></div><div><h3>Conclusions</h3><p>Oral semaglutide provided substantial glycemic and weight-loss benefits in adult individuals with T2DM.</p></div>\",\"PeriodicalId\":72796,\"journal\":{\"name\":\"Diabetes epidemiology and management\",\"volume\":\"14 \",\"pages\":\"Article 100209\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666970624000143/pdfft?md5=94b2da85bd56858ce5bfeb30f75ce245&pid=1-s2.0-S2666970624000143-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes epidemiology and management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666970624000143\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes epidemiology and management","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666970624000143","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

目的本研究旨在深入了解在常规医疗监护下，口服塞马鲁肽在沙特 T2DM 患者中的实际应用和效果。次要指标包括空腹血糖 (FBG)、体重和低血糖。结果本研究分析了 245 名未控制（HbA1c > 7 %）的 T2DM 患者。平均基线 HbA1c 为 10.1 % (1.2)。在 6 个月和 12 个月时，HbA1c 分别平均降低了 3.1 % (0.8) 和 3.2 % (0.8)。在开始使用塞马鲁肽前的最后三个月中，发生低血糖的频率为 4.4 (1.1)。在6个月和12个月的随访中，最后三个月发生低血糖的频率分别为2.2（0.8）和0.7（0.4）。在 6 个月和 12 个月的随访中，体重指数（BMI）的平均降幅分别为 13.0%（1.4）和 19.7%（3.4）。结论口服塞马鲁肽对患有 T2DM 的成年人有显著的降糖和减肥效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study

Aims

This study seeks to provide insights into the practical application and effects of oral semaglutide in Saudi T2DM patients under routine medical supervision.

Methods

The primary outcome measure was the laboratory HbA1c. Secondary measures included fasting blood glucose (FBG), weight, and hypoglycemia. All variables were checked after six months and 12 months of initiation.

Results

The analysis of this study included 245 uncontrolled (HbA1c > 7 %) T2DM patients. The mean baseline HbA1c was 10.1 % (1.2). HbA1c was reduced by an average of 3.1 % (0.8) and 3.2 % (0.8) at 6 and 12 months, respectively. The frequency of hypoglycemia events in the last three months before semaglutide was initiated was 4.4 (1.1). The frequency of hypoglycemia events in the last three months was 2.2 (0.8) and 0.7 (0.4) at 6-month and 12-month follow-up visits, respectively. The percent reduction in body mass index (BMI) was an average of 13.0 % (1.4) and 19.7 % (3.4) at six months and 12 months, respectively. Lipid profile and blood pressure were improved at six months and 12 months.